Dr. John Carlo Trials of Cabotegravir so successful, GSK ends trials early Tammye Nash | Managing Editornash@dallasvoice.com HIV Advocates this week applauded news of a new drug for use in pre-exposure prophylaxis regimens that has proven so successful in trials that the trials were ended early.
ViiV Healthcare — majority owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Limited as shareholders — had been testing a new, long-lasting injectible PrEP drug called Cabotegravir.